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INTRODUCTION: 
Oral route is the most commonly employed route of 
drug administration. Although different Route of 
administration are used for the delivery of drugs, oral 
route remain the preferred mode. The popularity of the 
oral route is attributed patient acceptance, ease of 
administration, accurate dosing, cost effective 
manufacturing method and generally improved shelf-
life of the product. Even for sustained release systems 
the oral route of administration has been investigated 
the most, because of flexibility in dosage forms design 
that the oral route offers. With many drugs, the basic 
goal of therapy is to achieve a steady-state blood level 
or tissue level that is therapeutically effective and non-
toxicfor an extended period of time.
1-4
 
Bi-layer tablet concept has long been utilized to develop 
sustained released formulation. Such 
Tablet has a fast releasing layer and may contain one 
(bi-layer), to sustain the drug release. The 
pharmacokinetic advantage relies on the criterion that, 
drug release from the fast releasing layer leads to a 
sudden rise in the blood concentration. However the 
blood level is maintained at steady state as the release 
from sustaining layer.
5-8
 
Baclofen is structural analogue of gamma-amino 
butyric acid is a centrally acting skeletal muscle 
relaxant, which is widely used in the treatment of 
spasticity resulting from multiple sclerosis, muscle 
spasms, muscular rigidity and spinal cord injuries.
9,10
 
Baclofen is rapidly absorbed from gastrointestinal tract 
and the peak plasma concentration is achieved within 
about 2 hr. It is largely excreted in the urine, 80% as 
unchanged drug and, the rest as metabolites. The 
elimination half-life has been reported to be 4 hr and 
thus make it a potent candidate for sustained release 
dosage form.
11,12
 
 
Figure 1: Structure of baclofen 
Chemical name: 4-Amino-3(p-chlorophenyl) butyric 
acid 
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ABSTRACT  
Aim of study was to develop bilayer drug delivery for treatment of spasticity by delivering loading and maintenance dose for 
fast achievement of peak plasma concentration and maintaining the same respectively. The prepared drug loaded bilayer tablets 
were evaluated for pre and post compression parameters. Stability study of the promising formulation was also performed. The 
tablets were prepared by direct compression and wet granulation method. The loading dose was delivered in the form of 
immediate release layer prepared by different super-disintegrations and maintenance dose was delivered through sustained 
release layer prepared by using polymers like HPMC K4, HPMC K15M, HPMC K100, PEO WSR 303 and Precirol. Both the 
immediate release layer and sustained release layers were separately optimized and then combined to optimize the 
bilayertablets. No interactions were found between drug and excipients. Formulation containing Kyron T314 shows immediate 
drug release. Formulation Containing PEO WSR 303 shows sustained release action and bilayer formulations F6 shows 
releases up to 24 hours. Bilayer tablets with release characteristics offer critical advantages such as, site specificity with 
improved absorption and efficacy. 
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Mechanism of action:  
Baclofenis is a structural analogue of g-amino butyric 
acid (GABA). Baclofen decreases spasticity by binding 
to GABAB receptors on presynaptic terminals of spinal 
interneurons. Binding to presynaptic GABAB receptors 
results in hyperpolarization of the membrane, which 
reduces Ca++ influx and decreases the release of the 
excitatory neurotransmitters, glutamate, and aspartate.
13
 
MATERIALS:  
Baclofen was obtained as gift sample from Unicure 
Pvt.remedies, Vadodara. SSG, Crospovidon, 
CrossCarmellose and Kyron T 314 were obtained as gift 
sample from colorcon, Goa. HPMC grades, ethyl 
cellulose, Carbopol 934, PVP K-30, Mannitol, and 
Magnesiumstearate, Talc were procured commercially 
from chem dyes corporation Vadodara.Precirol ATO 5 
was gift sample from GATTEFOSSÊ S.A.S., Mumbai, 
India, and PEO WSR 303 was gift sample from 
colorcon, Goa. 
METHOD OF PREPARATION: 
Direct compression was used for preparation of the 
immediate release layer and wet granulation technology 
was used for Sustained release layer containing 
baclofen. For both the layer, granulation was carried out 
separately, as follows: 
Preparation of immediate release layer (IR) 
All the ingredients were accurately weighed and passed 
through mesh 60#.In order to mix the ingredients 
thoroughly drug, superdisintegrant, microcrystalline 
cellulose, magnesium stearate and talc were mixed in a 
mortar and pestle. The powder was passed through 60# 
sieve and compressed on rotary tablet punching 
machine. (Made- Krishna Engineering) 
Preparation of sustained release layer (SR) 
It was performed by wet granulation method. The 
required amount of sustained release polymer were 
blended with baclofen and passed through 80 mesh 
sieve. Binding solution was prepared by dissolving 
required amount of PVP k 30 in iso propyl alcohol 
(IPA).Blended powders were granulated with IPA 
solution and sieved using 40 mesh sieves. The granules 
were dried at 45˚c for 30 min in tray dryer to evaporate 
the IPA and then lubricated with required amount of 
talc, magnesium stearate, store the lubricated granules 
with suitable label till it’s further used. 
Final compression of bilayer tablets 
Bilayer tablets were prepared by feeding 200 mg of SR 
granules manually into punch and compressed them 
with pre compression force. Then 100 mg of IR 
granules were manually fed into same die cavity SR 
granules and applied final compression force into rotary 
tablet punching machine. 
Evaluation parameter 
1. Physical appearance 
All the immediate and sustained release tablets were 
visually inspected for any tablet defects like capping, 
lamination, presence of any coloured particle. 
 
2. Hardness 
This can be determined by using Monsanto hardness 
tester. 
3. Friability 
Friability can be measured by Roche friability tester. 10 
tablets are kept in the friability tester and it is rotated at 
25 rpm for 4 minutes. Initial and final weights are then 
recorded and friability is calculated by following 
formula. 
%F = [1 − (Wt/W)] ∗ 100 
 W – Initial weight of tablet 
 Wt- Weight of tablet after revolution. 
 If % Friability of tablets is less than 1% is considered 
acceptable. 
4. Weight variation test 
 Weight variation test can be done as per the Indian 
Pharmacopoeia. 20 tablets   were generally taken and 
were weighed individually and the weight variation was 
calculated with the use of standard deviation. 
5. In Vitro drug release studies: 
In Vitro drug release studies were performed using USP 
dissolution test apparatus (Type 1). The dissolution 
studies were performed in 900ml of dissolution medium 
which was stirred at 50 rpm at 37±0.5°C following a pH 
progression method. i.e. pH 1.2 for first 2h, pH 6.8 for 
24hr. Aliquots was withdrawn periodically and replaced 
with fresh medium. 
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FORMULATION 
Table 1: Composition of immediate release layer tablet 
Immediate release layer 
 F1(mg) F2(mg) F3(mg) F4(mg) 
Baclofen 5 5 5 5 
Cros Povidone 2 - - - 
Cross Carmellose - 2 - - 
SSG - - 2 - 
Kyron T 314 - - - 2 
MCC 90 90 90 90 
Mg Stearate 2 2 2 2 
Talc 1 1 1 1 
Total  100 100 100 100 
 
Table 2: Composition of immediate release layer tablet 
Immediate release layer 
 F5(mg) F6(mg) F7(mg) F8(mg) 
Baclofen 5 5 5 5 
Cros Povidone 5 - - - 
Cross Carmellose - 5 - - 
SSG - - 5 - 
Kyron T 314    5 
MCC 87 87 87 87 
Mg Stearate 2 2 2 2 
Talc 1 1 1 1 
Total  100 100 100 100 
 
Table 3: Composition of sustained release layertablet 
Sustained release layer 
 F1(mg) F2(mg) F3(mg) F4(mg) F5(mg) F6(mg) 
Baclofen 21 21 21 21 21 21 
HPMC K4 M 60 - - - - - 
HPMC K15 M - 60 - - - - 
HPMC K 100 M - - 60 - - - 
PEO WSR 303 - - - 20 40 60 
PVP K 30 10 10 10 10 10 10 
DCP 103 103 103 143 123 103 
Magnesium Stearate 4 4 4 4 4 4 
Talc 2 2 2 2 2 2 
IPA q.s q.s q.s q.s q.s q.s 
Total 200 200 200 200 200 200 
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Table 4: Composition of sustained release layertablet 
Sustained release layer 
 F7 
(mg) 
F8 
(mg) 
F9 
(mg) 
F10 
(mg) 
F11 
(mg) 
F12 
(mg) 
F13 
(mg) 
F14 
(mg) 
F15 
(mg) 
Baclofen 21 21 21 21 21 21 21 21 21 
Ethyl cellulose 20 40 60 - - - - - - 
Carbopol - - - 10 20 40 - - - 
Precirol - - - - - - 40 60 80 
PVP K 30 10 10 10 10 10 10 10 10 10 
DCP 143 123 103 153 143 123 123 103 83 
Mg. Stearate 4 4 4 4 4 4 4 4 4 
Talc 2 2 2 2 2 2 2 2 2 
IPA q.s q.s q.s q.s q.s q.s q.s q.s q.s 
Total 200 200 200 200 200 200 200 200 200 
 
RESULT: 
The results of evaluation parameters of formulations 
F1-F8 were calculated and described in this. 
Precompression parameters such as Angle of Repose, 
Loose Bulk Density, Tapped Bulk Density, Hausner’s 
Ratio, and Carr’s Index. Values are listed in Table 5.
 
Table 5: Pre compression study of immediate release layer tablets 
Batches Bulk Density  
gm. cm
-3
 (+S.D) 
(n=3) 
Tapped density        
gm. cm
-3
 (+S.D) 
(n=3) 
Carr’s Index (+ 
S.D) 
(n=3) 
Hausner’s ratio 
(+S.D) 
(n=3) 
Angle of repose 
(ϴo) (+S.D) 
(n=3) 
F1 0.29+ 0.058 0.36+ 0.07 12.1+ 0.12 1.13+ 0.22 28.45+ 0.02 
F2 0.30+ 0.06 0.33+ 0.06 9.09+ 0.18 1.11+ 0.222 27.36+ 0.01 
F3 0.33+ 0.066 0.4+ 0.08 17.5+ 0.01 1.21+ 0.24 30.49+ 0.05 
F4 0.24+ 0.048 0.43+ 0.086 14.5+ 0.11 1.18+ 0.23 31.27+ 0.03 
F5 0.29+ 0.058 0.31+0.062 12.1+ 0.08 1.13+ 0.22 30.72+ 0.02 
F6 0.30+ 0.06 0.37+ 0.074 6.09+ 0.09 1.14+0.23 29.45+ 0.06 
F7 0.35+ 0.07 0.48+ 0.096 17.5+ 0.16 1.24+ 0.25 28.12+ 0.01 
F8 0.33+ 0.066 0.4+ 0.08 16.3+ 0.13 1.20+ 0.24 30.80+ 0.08 
 
Table 6: Pre compression study of sustained release layer tablets 
Batches Bulk Density  
gm cm
-3
 (+S.D 
(n=3) 
Tapped density        
gm cm
-3
 (+S.D) 
(n=3) 
Carr’s Index (+ 
S.D) 
(n=3) 
Hausner’s ratio 
(+S.D) 
(n=3) 
Angle of repose 
(ϴo) (+S.D) 
(n=3) 
F1 0.24+ 0.04 0.63 ± 0.12 15.85 ±0.12 1.18 ±0.23 29.19 ±0.02 
F2 0.28+ 0.05 0.62 ± 0.124 17.74 ±0.18 1.21 ± 0.24 29.65 ±0.05 
F3 0.30+ 0.06 0.54 ± 0.108 21.62 ±0.04 1.19 ±0.23 27.34 ±0.42 
F4 0.29+ 0.058 0.64 ± 0.128 14.06 ±0.05 1.16 ±0.232 29.62 ±0.31 
F5 0.32+ 0.064 0.52 ± 0.10 20.63 ±0.07 1.26 ± 0.25 28.51 ±0.25 
F6 0.38+ 0.07 0.58 ± 0.11 17.74 ±0.01 1.21 ± 0.24 27.19 ±0.43 
F7 0.34+ 0.068 0.62 ± 0.12 19.62 ±0.21 1.20 ±0.24 28.37 ±0.67 
F8 0.40+0.066 0.58 ± 0.11 22.66 ±0.08 1.15 ±0.23 26.34 ±0.26 
F9 0.48+ 0.09 0.62 ± 0.12 21.62 ±0.07 1.28 ± 0.25 25.26 ±0.05 
F10 0.31+0.062 0.54± 0.10 18.53 ±0.11 1.12± 0.22 29.57± 0.91 
F11 0.42+ 0.084 0.46±0.09 20.12± 0.07 1.24± 0.25 30.12± 0.02 
F12 0.37+ 0.074 0.48±00.096 16.61± 0.05 1.14± 0.23 24.28± 0.85 
F13 0.35+ 0.07 0.44±0.08 11.23± 0.13 1.18± 0.23 30.64±0.12 
F14 0.32+ 0.064 0.50±0.1 15.67± 0.04 1.15± 0.23 31.05±0.21 
F15 0.47+0.09 0.51± 0.10 16.67± 0.15 1.14±0.22 29.42± 0.88 
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The results of evaluation parameters of formulations 
F1-F15 were calculated and described in this. 
Precompression parameters such as Angle of Repose, 
Loose Bulk Density, Tapped Bulk Density, Hausner’s 
Ratio, and Carr’s Index. Values are listed in Table 6. It 
was found that granules of all batched of wet 
granulation were found having fair-passable flow 
property. 
The result of post compression evaluation parameters of 
formulations F1-F15 such as hardness, friability, weight 
variation and drug content is given in table no 7. 
 
Table 7: Post compression study of bilayer layer tablet 
Batches Hardness   (kg cm
-2
+  
S.D) (n=3) 
Friability (%) Weight variation Avg 
weight (mg)(S.D < 10%) 
% Drug Content 
(S.D) 
F1 6± 0.42 0.61 ± 0.12 300± 0.04 100± 0.01 
F2 5± 0.39 0.66 ± 0.13 301± 0.09 101± 0.08 
F3 7± 0.35 0.38 ± 0.07 300± 0.10 101± 0.10 
F4 6± 0.46 0.33 ± 0.06 301± 0.14 99.98± 0.15 
F5 7± 0.50 0.26 ± 0.05 299± 0.18 98.87± 0.17 
F6 5± 0.59 0.37 ± 0.07 304± 0.13 100± 0.09 
F7 7± 0.46 0.49± 0.09 301± 0.43 99.52± 0.13 
F8 6± 0.57 0.20 ± 0.04 298.8± 0.36 99.48± 0.11 
F9 7± 0.62 0.57 ± 0.11 297± 0.21 97.39± 0.04 
F10 5± 0.21 0.36± 0.07 300± 0.38 99.19± 0.17 
F11 6± 0.53 0.29± 0.05 301±0.09 100± 0.15 
F12 7± 0.60 0.64± 0.12 299.8± 0.9 100± 0.06 
F13 7± 0.76 0.52± 0.10 299.6± 0.38 99.53± 0.25 
F14 5± 0.66 0.41± 0.08 300± 0.44 99.89± 0.12 
F15 7± 0.95 0.50± 0.1 301± 0.32 99.54± 0.24 
 
In-Vitro Drug Release data of batch F1 to F15 were shown in figures given below. 
6. In Vitro Dissolution Study 
 
Figure 2: In Vitro Dissolution Study of Immediate release layer tablet F1 to F3 
 
 
Figure 3: In Vitro Dissolution Study of Immediate release layer tablet F5 to F6 
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Figure 4: In Vitro Dissolution Study of Sustained release layer tablet F7 to F9 
 
 
Figure 5: In Vitro Dissolution Study of Sustained release layer tablet F10 to F12 
 
 
Figure 6: In Vitro Dissolution Study of Sustained release layer tablet F7 to F9 
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DISCUSSION 
In Bilayer tablet of Baclofen immediate release layer 
was prepared by direct compressionand sustained 
release was prepared by wet granulation method. The 
Tablets Containing PEO WSR 303 polymer showed the 
desired sustained action. Formulations F6 releases up to 
24 hours and it shows good sustained action. In all the 
formulations an initial burst release was seen to provide 
the loading dose of the drug, followed by the controlled 
release. From these results it clearly indicates that the 
prepared formulations are potential of the Baclofen 
bilayer matrix tablet as an alternative to the 
conventional dosage form. Batch F7-F9 containing 
ethyl cellulose not shows the retardation of drug at 
lower concentration. Ethyl cellulose shows sustain 
action up to 8 hrs.   HPMC different viscosity grades, 
PEO WSR 303 and Carbopol 934 shows retardation of 
drug. A higher viscosity polymer shows desired 
retardation up to 24 hr. 
CONCLUSION:  
In vitro release studies demonstrated that the release of 
Baclofen from the prepared bi-layer matrix tablets were 
dependent on polymeric level. When we increased the 
polymeric concentration, due to this increased 
concentration of sustained release polymers drug 
release was retarded up to 24 hr. In all the formulations 
an initial burst release was seen to provide the loading 
dose of the drug, followed by the controlled release for 
24 hr  From these results it clearly indicates that the 
prepared formulations are potential of the Baclofen bi-
layer matrix tablet as an alternative to the conventional 
dosage form. 
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